those undergoing this particular procedure (5) . Cultures of CMV from leukocytes raised the question of risk, and studies by Prince et al. (6) seemed to indicate that there was a direct relation between the number of units transfused and the risk of CMV infection. The risk was approximately 5% per unit transfused, and neither use of fresh blood nor the antibody status of the recipient seemed to be a determining factor.
At about the same time, CMV was implicated as a causative problem in renal transplants, supposedly being involved in generalized infection, interstitial pneumonia, and possibly the rejection of the transplant. However, most of these infections are probably asymptomatic, and the problem of interpreting their role is complicated by the use of steroids and immunosuppressants in the recipient.
The mode of acquisition of the CMV infection is also a particularly vexing problem. The virus could be acquired from exogenous sources such as the environment, the transfused blood, or the donated kidney. On the other hand, it's quite possible that the virus is acquired endogenously or by reactivation of a virus already present in the recipient at the time of transplantation. The assumption has commonly been made that those recipients that are seronegative to CMV at the time of transplant probably acquire their infection exogenously, whereas those individuals who are seropositive at the time of transplant acquire their infection by reactivation, or endogenously. For several reasons, there is no real proof that this assumption is correct. There is a question of the sensitivity of the antibody tests used to detect CMV, be it complement fixation, immunofluorescence, indirect hemagglutination, or some other more sophisticated technique. In addition, there is evidence to indicate that a person may have antibody at one point in time and then over the course of months to years lose that antibody, appear to be antibody negative and then, once again, manifest the presence of antibody. Since there are a number of CMV strains, complete reliability of antibody tests using any one particular strain as an antigen is questionable.
We have been studying babies undergoing exchange transfusion in attempt to shed more light on this problem of endogenous versus exogenous sources of infection. We theorized that an infant who was antibody negative at the time of exchange transfusion would have had little, if any, chance to have lost previously existing antibody and thus would constitute a truly susceptible individual without previous experience with CMV. In addition, we were interested in knowing the risk of acquiring CMV infection as well as any symptoms and signs which might accompany acquisition of this particular agent. Babies, mothers, and blood donors were studied serologically and virologically before transfusion, as well as 6 and 12 weeks post-transfusion. The serological studies consisted of complement fixation (CF) antibody determinations, while virological studies consisted of cultures of throat, urine, and buffy coat at the time of exchange transfusion and follow-up cultures 6 and 12 weeks later. Control infants matched for age, sex, weight, and race together with control mothers were evaluated in a similar manner to the study infants, except that buffy-coat cultures were not done. Studies have been completed on 24 babies who have undergone at least one exchange transfusion. These babies have received a total of 34 units of blood. Six infants were antibody negative before exchange transfusion, and 18 infants were antibody positive; no infants were culture positive at the time of exchange transfusion. Of the 20 infants in the control group, 11 were antibody positive and none were culture positive. The results are shown in Table 1 . Five of the study infants became infected with cytomegalovirus 6 to 12 weeks after exchange transfusion. Of the six infants who were antibody negative, two received blood from antibody-positive donors and one of these became infected. Four infants received blood from antibody negative donors, and one of these became infected. Of the 18 infants who were antibody positive, 12 received blood from antibody-positive donors and three became infected. Six patients received blood from antibody-negative donors and none became infected. None of the control infants became infected during the study period; and all of the infants, regardless of whether they became infected or not, remained asymptomatic, and their CBC's remained within normal limits. One mother of a transfused infant developed cytomegaloviruria, but the child remained negative. All cultures from control mothers and blood donors remained negative. In summary, 21 % of exchange-transfused infants became infected, transplacental antibody was not protective, a donor with complement-fixation antibody was somewhat more likely to be the source of infection than an antibody-negative donor, and no clinical disease was detected in this particular study population. These data strongly suggest that cytomegalovirus infection may be transmitted by blood transfusion even though it is not possible to culture virus from the blood used, and that acquisition of infection, at least in this small number of patients, is most likely to be asymptomatic.
